Drugs that contain Suvorexant
1. List of Belsomra drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7951797 | MERCK SHARP DOHME | Substituted diazepan orexin receptor antagonists |
Nov, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098892 | MERCK SHARP DOHME | Solid dosage formulations of an orexin receptor antagonist |
May, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Jan 29, 2023 |
Market Authorisation Date: 13 August, 2014
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
More Information on Dosage
BELSOMRA family patents
12
United States
4
Australia
4
Russia
4
China
4
Japan
3
Korea, Republic of
3
European Union
2
Mexico
2
Argentina
2
Brazil
2
Chile
2
Taiwan, Province of China
2
Ukraine
2
Canada
1
South Africa
1
Denmark
1
El Salvador
1
Hong Kong
1
Slovenia
1
Morocco
1
Norway
1
Costa Rica
1
Colombia
1
Croatia
1
Honduras
1
Portugal
1
Cyprus
1
Malaysia
1
Spain
1
Peru
1
Poland
1
Dominican Republic
1
RS
1
Ecuador
1
Nicaragua
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic